BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/140/0.1/20.12.24 Share Price

Warrant

P20YV7

NLBNPIT20YV7

Market Closed - Borsa Italiana 01:04:29 06/07/2024 am IST
0.04 EUR -6.98% Intraday chart for BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/140/0.1/20.12.24
3 months-79.90%
Date Price Change
06/24/06 0.04 -6.98%
04/24/04 0.043 0.00%
03/24/03 0.043 +14.67%
02/24/02 0.0375 -2.60%
01/24/01 0.0385 -4.94%

Real-time Borsa Italiana

Last update July 06, 2024 at 01:04 am IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer BNP Paribas BNP Paribas
P20YV7
ISINNLBNPIT20YV7
Date issued 21/03/2024
Strike 140 $
Maturity 20/12/2024 (168 Days)
Parity 10 : 1
Emission price-
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.372
Lowest since issue 0.036
Delta0.05x
Omega 9.023
Premium75.58x
Gearing185.66x
Moneyness 0.5713
Difference Strike 59.92 $
Difference Strike %+42.80%
Spread 0.0235
Spread %45.63%
Theoretical value 0.0408
Implied Volatility 43.85 %
Total Loss Probability 97.42 %
Intrinsic value 0.000000
Present value 0.0408
Break even 140.44 €
Theta-0.01x
Vega0.01x
Rho0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
73.92 EUR
Average target price
103.5 EUR
Spread / Average Target
+40.05%
Consensus
  1. Stock Market
  2. Warrants
  3. P20YV7 Warrant